{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:14:10Z","timestamp":1790702050461,"version":"4.1.0"},"reference-count":142,"publisher":"Maad Rayan Publishing Company","issue":"4","content-domain":{"domain":["apb.tbzmed.ac.ir"],"crossmark-restriction":false},"short-container-title":["Adv Pharm Bull"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:p>The overall purpose of rheumatoid arthritis (RA) treatment is to give symptomatic alleviation; there is no recognized cure for RA. Frequent use of potent drugs like non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), lead to various adverse effects and patient compliance suffers. On the other hand, there are many drawbacks associated with traditional methods, such as high first pass, high clearance rate, and low bioavailability. Drug administration through the skin can be a promising alternative to cope with these drawbacks, increasing patient compliance and providing site-specific action. The stratum corneum, the uppermost non-viable epidermal layer, is one of the primary limiting barriers to skin penetration. Various nanocarrier technologies come into play as drug vehicles to help overcome these barriers. The nanocarrier systems are biocompatible, stable, and have a lower cytotoxic impact. The review discusses several lipid-based nanocarrier systems for anti-rheumatic medicines for topical administration it also discusses in-vivo animal models for RA and provides information on patents granted.<\/jats:p>","DOI":"10.34172\/apb.2023.075","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T05:49:21Z","timestamp":1686721761000},"page":"663-677","update-policy":"https:\/\/doi.org\/10.34172\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Lipid Nano-System Based Topical Drug Delivery for Management of Rheumatoid Arthritis: An Overview"],"prefix":"10.34172","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-760X","authenticated-orcid":true,"given":"Komal Diliprao","family":"Dhule","sequence":"first","affiliation":[{"name":"Dr. D. Y. Patil Institute of Pharmaceutical Science and Research, Pimpri, Pune 411018, Department of Pharmaceutics, Pune, Maharashtra, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-4188","authenticated-orcid":true,"given":"Tanaji Dilip","family":"Nandgude","sequence":"additional","affiliation":[{"name":"Dr. D. Y. Patil Institute of Pharmaceutical Science and Research, Pimpri, Pune 411018, Department of Pharmaceutics, Pune, Maharashtra, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"20123","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026616666160530152354"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01661"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1021\/mp2000742"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(01)06075-5"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041606"},{"key":"R7","unstructured":"Benjamin O, Goyal A, Lappin SL. Disease-modifying antirheumatic drugs (DMARD). In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023."},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111880"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.3.1.127"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834518a3"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/536962"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/480291"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep005"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2011.10.006"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2000.16641"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/978351"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565130-00008"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464120-00001"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hermed.2020.100412"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7110067"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1089\/act.2006.12.22"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcme.2022.01.005"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2004.10.971"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2005.08.003"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1983780"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114368"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1590\/s1984-82502016000300015"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-00909-6"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.09.016"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018020856"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-014-0214-0"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1007\/s12668-021-00871-0"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2005.06.004"},{"key":"R34","first-page":"43","article-title":"Nanoemulsion and nanoemulgel as a topical formulation","volume":"5","author":"Chellapa P","year":"2015","journal-title":"IOSR J Pharm"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108622"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2020.989"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2016.1218462"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00801-6"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2013.10.015"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v9i4.3143"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1632"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040454"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071004"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.3109\/21691401.2014.883401"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1211\/0022357044445"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1039\/d1bm01438b"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2016-0405"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.07.060"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.52711\/0974-360x.2022.00154"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.661"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2018.1504963"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s135749"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1778"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2015.1048553"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2021v13i2.39526"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2020.111262"},{"key":"R57","doi-asserted-by":"crossref","unstructured":"Pattnaik S, Swain K, Singh SP, Sirbaiya AK. Lipid vesicles: potentials as drug delivery systems. In: Mozafari M, ed. Nanoengineered Biomaterials for Advanced Drug Delivery. Elsevier; 2020. p. 163-80. doi: 10.1016\/b978-0-08-102985-5.00008-5.","DOI":"10.1016\/B978-0-08-102985-5.00008-5"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/873653"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2003.10.032"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-017-0939-2"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091457"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119558"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.3.6.727"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2012.724472"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02166-9"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.4103\/2231-4040.85524"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2053761"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.30750\/ijpbr.2.2.2"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2013.871601"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.4103\/0110-5558.72415"},{"key":"R71","doi-asserted-by":"publisher","DOI":"10.1615\/critrevtherdrugcarriersyst.v20.i1.20"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.52711\/0975-4377.2022.00012"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/161943"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.2174\/1567201817666200724170203"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1016\/j.matpr.2021.09.239"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.17756\/nwj.2016-030"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.5530\/ijper.55.1s.33"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s86186"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0489-z"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s188842"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-020-00117-y"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121878"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2011.01.020"},{"key":"R84","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9324567"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1007\/s00289-015-1544-8"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2013.841783"},{"key":"R87","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200114090659"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.1208\/pt0804086"},{"key":"R89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2004.09.006"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.11.003"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.03.013"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.03.033"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030563"},{"key":"R94","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2018.10.008"},{"key":"R95","doi-asserted-by":"crossref","unstructured":"Newton AM, Kaur S. Solid lipid nanoparticles for skin and drug delivery: methods of preparation and characterization techniques and applications. In: Grumezescu AM, ed. Nanoarchitectonics in Biomedicine. William Andrew Publishing; 2019. p. 295-334. doi: 10.1016\/b978-0-12-816200-2.00015-3.","DOI":"10.1016\/B978-0-12-816200-2.00015-3"},{"key":"R96","doi-asserted-by":"crossref","unstructured":"Badilli U, Gumustas M, Uslu B, Ozkan SA. Lipid-based nanoparticles for dermal drug delivery. In: Grumezescu AM, ed. Organic Materials as Smart Nanocarriers for Drug Delivery. William Andrew Publishing; 2018. p. 369-413. doi: 10.1016\/b978-0-12-813663-8.00009-9.","DOI":"10.1016\/B978-0-12-813663-8.00009-9"},{"key":"R97","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2013.07.010"},{"key":"R98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.02.017"},{"key":"R99","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802712590"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017019047"},{"key":"R101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.11.024"},{"key":"R102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2022.04.031"},{"key":"R103","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2020v12i3.36863"},{"key":"R104","doi-asserted-by":"publisher","DOI":"10.1039\/d2tb00031h"},{"key":"R105","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2021.117053"},{"key":"R106","first-page":"6","article-title":"Nanoemulsion-based gel formulation of aceclofenac for topical delivery","volume":"1","author":"Modi JD","year":"2011","journal-title":"Int J Pharm Pharm Sci Res"},{"key":"R107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.04.052"},{"key":"R108","doi-asserted-by":"publisher","DOI":"10.1186\/1477-3155-6-8"},{"key":"R109","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s294653"},{"key":"R110","doi-asserted-by":"publisher","DOI":"10.17795\/jjnpp-17653"},{"key":"R111","doi-asserted-by":"publisher","DOI":"10.37285\/ijpsn.2010.3.2.12"},{"key":"R112","doi-asserted-by":"publisher","DOI":"10.21776\/ub.rjls.2016.003.01.6"},{"key":"R113","first-page":"35","article-title":"Formulation and evaluation of prednisolone proliposomal gel for effective topical pharmacotherapy","volume":"4","author":"Kurakula M","year":"2012","journal-title":"Int J Pharm Sci Drug Res"},{"key":"R114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.10.032"},{"key":"R115","doi-asserted-by":"publisher","DOI":"10.2478\/acph-2022-0006"},{"key":"R116","first-page":"38","article-title":"Formulation and evaluation of ufasomal topical gel containing selected nonsteroidal anti-inflammatory drug (NSAIDs)","volume":"13","author":"Lakshmi VS","year":"2021","journal-title":"J Pharm Sci Res"},{"key":"R117","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/680580"},{"key":"R118","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2020-0316"},{"key":"R119","doi-asserted-by":"publisher","DOI":"10.4103\/0250-474x.78524"},{"key":"R120","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360x.2017.00541.8"},{"key":"R121","doi-asserted-by":"publisher","DOI":"10.2174\/2210303108666180216151234"},{"key":"R122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2018.07.015"},{"key":"R123","first-page":"73","article-title":"Formulation and evaluation of nanostructured lipid carrier (NLC) of lornoxicam","volume":"6","author":"Dandagi PM","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"R124","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s99198"},{"key":"R125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.03.047"},{"key":"R126","doi-asserted-by":"publisher","DOI":"10.1002\/art.27503"},{"key":"R127","doi-asserted-by":"crossref","unstructured":"Jones GW, Hill DG, Sime K, Williams AS. In vivo models for inflammatory arthritis. In: Jenkins BJ, ed. Inflammation and Cancer. New York, NY: Humana Press; 2018. p. 101-18. doi: 10.1007\/978-1-4939-7568-6_9.","DOI":"10.1007\/978-1-4939-7568-6_9"},{"key":"R128","first-page":"377","article-title":"Animal models of rheumatoid arthritis","volume":"1","author":"Bendele A","year":"2001","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R129","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2015.1125917"},{"key":"R130","unstructured":"Funk M, Schulze B, Guenzi E, Michaelis U, Bohnenkamp H, Eichhorn M, et al. Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis. United States Patent Application US 12\/300,448. 2009. https:\/\/patents.google.com\/patent\/WO2007134819A1\/en."},{"key":"R131","unstructured":"Fahmy TM, Look M, Craft J. Nanolipogel Comprising a Polymeric Matrix and a Lipid Shell. United States Patent US 10,709,664. 2020. https:\/\/patents.google.com\/patent\/US10709664B2\/en."},{"key":"R132","unstructured":"Sachdeva MS, Patlolla R. Nanoparticle Formulations for Skin Delivery. United States Patent US 8,715,736. 2014. https:\/\/patents.google.com\/patent\/US8715736B2\/en."},{"key":"R133","unstructured":"https:\/\/patents.google.com\/patent\/NZ244966A\/en."},{"key":"R134","unstructured":"Ghiassian SD, Mellors TR, Santolini M, Ameli A, Schoenbrunner N, Akmaev VR, Jet al. Method of Treating a Subject Suffering from Rheumatoid Arthritis with Anti-TNF Therapy Based on a Trained Machine Learning Classifier. United States Patent US 11,195,595. 2021. https:\/\/patents.google.com\/patent\/US11195595B2\/en."},{"key":"R135","unstructured":"Kupper H, Kent JD, Cifaldi MA, Perez JL, inventors; AbbVie Biotechnology Ltd, assignee. Uses and compositions for treatment of rheumatoid arthritis. United States patent application US 15\/216,328. 2017 Jun 8. https:\/\/patents.google.com\/patent\/US20080131374A1\/en."},{"key":"R136","unstructured":"Huang X, Jasson M, Marks V, Radin A, inventors; Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc, assignee. Compositions for the treatment of rheumatoid arthritis and methods of using same. United States patent application US 17\/133,870. 2021 Jul 29."},{"key":"R137","unstructured":"Hartle S, Leclair S, Shebl A, Steidl S, Brocks B, Della Ducata D, Rosport K, inventors; Morphosys AG, assignee. Treatment for rheumatoid arthritis. United States patent US 10,913,792. 2021."},{"key":"R138","unstructured":"Sabourault NL, De Faveri C, Sheikh A. Novel Salts and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders. Google Patents. 2015."},{"key":"R139","unstructured":"https:\/\/patents.google.com\/patent\/EP2680884B1\/en."},{"key":"R140","unstructured":"https:\/\/patents.google.com\/patent\/CN102597268B\/en."},{"key":"R141","unstructured":"https:\/\/patents.google.com\/patent\/CA2760460C\/en."},{"key":"R142","unstructured":"https:\/\/patents.google.com\/patent\/AU2018260845B2\/en."}],"container-title":["Advanced Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/apb.tbzmed.ac.ir\/PDF\/apb-13-663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/apb.tbzmed.ac.ir\/PDF\/apb-13-663.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T07:15:24Z","timestamp":1699427724000},"score":1,"resource":{"primary":{"URL":"https:\/\/apb.tbzmed.ac.ir\/Article\/apb-38025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":142,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.34172\/apb.2023.075","relation":{},"ISSN":["2228-5881","2251-7308"],"issn-type":[{"value":"2228-5881","type":"print"},{"value":"2251-7308","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"Tabriz University of Medical Sciences","name":"journal_owner","label":"Journal Owner"},{"value":"Tabriz University of Medical Sciences","name":"journal_publisher","label":"Journal Publisher"},{"value":"2022-07-12","order":1,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}